louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04480398: Efficacy and Safety of Guduchi Ghan Vati for Covid-19 Asymptomatic Patients
Official title: A Retrospective Study on Efficacy and Safety of Guduchi Ghan Vati for Covid-19 Asymptomatic Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Covid19
Asymptomatic Condition
Keywords: Ayurveda
Guduchi Ghan Vati
Lead sponsor: Aarogyam UK
Sponsor class: OTHER
Collaborators: name: Dr. Sarvepalli Radhakrishnan Rajasthan Ayurved University
name: Samta Ayurveda Prakoshtha, India
First posted: 2020-07-21
Enrollment: 91
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Covid-19 Confirmed Asymptomatic patients

Brief summary: Coronavirus disease 2019 (Covid-19) has been declared global emergency with immediate safety, preventative and curative measures to control the spread of virus. Confirmed cases are treated with clinical management as they are diagnosed but so far, there is no effective treatment or vaccine yet for Covid-19.

With recommended guidelines of AYUSH Ministry, India, the use of Ayurveda for Covid-19 has increased; however, its efficacy and safety in Covid-19 confirmed patients remain unclear.

Present study examined the efficacy and safety of one of the recommended Ayurveda drug (Guduchi Ghan Vati) compared with standard care for patients with asymptomatic Covid-19 patients.


Eligibility criteria: Inclusion Criteria:

* Age over 18
* A person diagnosed with COVID-19
* Asymptomatic at the time of admission

Exclusion Criteria:

* Patients over 75 years
* Taking antibiotics or antiretroviral for any reason
* Mild to Moderate symptoms at the time of hospital admission

Primary outcomes:
measure: Virologic clearance
timeFrame: 21 days
Secondary outcomes:
measure: Change in the number of patients going from asymptomatic to moderately disease
timeFrame: 10-days of hospital admission
measure: Hospital Stay
timeFrame: 21 days
measure: Clinically relevant adverse effects
timeFrame: 21-days
Other outcomes:
Locations:
city: Jodhpur
country: India
facility: Dr Sarvepalli Radhakrishnan Rajasthan Ayurved University
state: Rajasthan
Study officials:
affiliation: Samta Ayurveda Prakoshtha
name: Parashar Sharma
role: STUDY_CHAIR
affiliation: Aarogyam UK
name: Jaydeep Joshi
role: STUDY_CHAIR
affiliation: Aarogyam UK
name: Neha Sharma
role: STUDY_DIRECTOR
affiliation: Dr. Sarvepalli Radhakrishnan Rajasthan Ayurved University
name: Abhimanyu Kumar
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00079898: Effect of Acupuncture on Human Brain Activity
Official title: Modulatory Effect of Acupuncture on Human Brain Activity
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH)
Sponsor class: NIH
First posted: 2004-03-19
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP

Brief summary: The purpose of this study is to use brain imaging technology to examine the way acupuncture affects brain function.

Detailed description: Acupuncture is emerging as an important procedure in complementary medicine. Its mechanism of action remains unclear, but research suggests that its effects are mediated through a widely connected network that is involved in the regulation of mood, behavior, and function of physiological systems. This study will use functional magnetic resonance imaging (fMRI) to monitor the effects of manual acupuncture on the brain function of study participants.

Participants in this study will undergo acupuncture one needle at a time. Researchers will then ask participants questions about how they feel and will compare the sensations reported by participants to their images of brain response.

Eligibility criteria: Inclusion Criteria:

* In good physical health

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Massachusetts General Hospital
name: Kathleen Hui, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Hui KK, Liu J, Makris N, Gollub RL, Chen AJ, Moore CI, Kennedy DN, Rosen BR, Kwong KK. Acupuncture modulates the limbic system and subcortical gray structures of the human brain: evidence from fMRI studies in normal subjects. Hum Brain Mapp. 2000;9(1):13-25. doi: 10.1002/(sici)1097-0193(2000)9:13.0.co;2-f.
Clinical trial NCT01541098: A Clinical Study of Lyophilized Plasma in Patients on Warfarin
Official title: A Phase II Clinical Study of Lyophilized Plasma in Patients on Warfarin
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Anticoagulant Therapy
Lead sponsor: HemCon Medical Technologies, Inc
Sponsor class: INDUSTRY
First posted: 2012-02-29
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This is a multi center, phase 2 randomized controlled study to determine the effect of lyophilized plasma in patients on warfarin therapy.


Eligibility criteria: Inclusion Criteria

1. Patients receiving oral anticoagulation with warfarin derived agents.
2. Patients who have need for urgent surgery, an invasive procedure or identification of a patient with active bleeding where oral or parenteral vitamin K therapy is deemed too slow in its action for reversal of warfarin anticoagulant effects.
3. Patients with an elevated international normalized ratio.

Exclusion Criteria

1. Patients who are clinically unstable.
2. Patients who have congenital or acquired coagulopathies (other than warfarin therapy).
3. Patients who have received medications that could interfere with the results of laboratory testing.
4. Pregnant or nursing women.
5. Patients participating in another clinical treatment study currently or during the past 1 month prior to study inclusion.
6. Patients previously enrolled in this study.
7. Active illicit drug use.

Primary outcomes:
measure: Assess and Compare Adverse Events
timeFrame: Duration of Study (Less than or equal to 72 hours)
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01654198: PET/CT in Psoriatic Arthritis
Official title: FDG-PET/CT in the Diagnosis and Monitoring of Psoriatic Arthritis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Psoriatic Arthritis
Lead sponsor: University of Pennsylvania
Sponsor class: OTHER
First posted: 2012-07-31
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with psoriatic arthritis defined by CASPAR criteria and active joint disease.

Brief summary: When patients with psoriasis develop joint pain, it is often hard to decide whether or not the pain is due to psoriatic arthritis (PsA). At this time, doctors use information from the history and physical exam to determine the diagnosis. X-rays, magnetic resonance imaging (MRI) and ultrasound have been used to help with the diagnosis but all three have limitations. A newer imaging technique, whole body Positron Emission Tomography/Computed Tomography (PET/CT) uses the idea that inflammatory cells take up sugar to locate inflammation in the body. Because patients with PsA have inflammatory cells in their joints and tendons, this type of scan allows the physician to take a picture of the whole body and locate inflammation. The investigators have found that some patients with psoriasis (but without arthritis) have inflammation in joints and tendons even before the patient has symptoms. In this study, the investigators will explore how well PET/CT works for assessing inflammation in patients with PsA. This would be a very exciting tool that could be used to find and treat inflammation before it causes damage or pain.


Eligibility criteria: Inclusion Criteria:

* Age 18-80,
* active psoriatic arthritis (joint or enthesis inflammation)

Exclusion Criteria:

* Diabetes,
* pregnant,
* no active PsA

Primary outcomes:
measure: Primary outcome is inflammation as measured by SUVmax and metabolic volumetric product in the joints and entheses.
timeFrame: At the discretion of the PI
Secondary outcomes:
measure: Correlation of local inflammation in joints and enthesis with systemic inflammatory markers including IL6 and high sensitivity CRP.
timeFrame: At the discretion of the PI
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: University of Pennsylvania Division of Rheumatology
state: Pennsylvania
Study officials:
affiliation: University of Pennsylvania
name: Alexis R Ogdie, MD, MSCE
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00205998: Surgical Plate Osteosynthesis of Distal Radius Fractures
Official title: Surgical Plate Osteosynthesis of Distal Radius Fractures. Prospective Study of the Locking Compression Plate (LCP)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Distal Radius Fractures
Keywords: Locking Compression Plate
Conservative treatment
Surgical treatment
Radius fractures
AO 23
Lead sponsor: AO Innovation Translation Center
Sponsor class: OTHER
Collaborators: name: Synthes Inc.
name: AO Hand Expert Group
First posted: 2005-09-21
Enrollment: 450
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Primary objective of the study is to demonstrate specific indications for the

surgical treatment of distal radius fractures using the locking compression

plate.

Detailed description: In addition the differences between the surgical treatment compared to

conservative treatment with respect to fracture healing, functional outcome

and subject satisfaction will be analysed after 6w./6m./1y./2y.

Eligibility criteria: Inclusion Criteria:

* skeletally mature female and male
* Distal radius and ulnar fractures AO 23
* 10 days after injury

Exclusion Criteria:

* general or local conditions adversely affecting the bone physiology
* ISS \>16
* osteosynthesis close to the wrist joint where a different implant has been used
* history of drug and alcohol abuse

Primary outcomes:
measure: - Document specific indications for the surgical treatment of distal radius fractures using the LCP
Secondary outcomes:
measure: - Primary reduction and maintenance of reduction of the plate fixation
measure: - Functional outcome scoring using "Garetland and Werley, DASH and SF-36 scoring
measure: - Patient and surgeon satisfaction
measure: - Analysis of the occured complications
Other outcomes:
Locations:
city: Boston
country: United States
facility: Harvard Medical School
state: Massachusetts
city: Ludwigshafen
country: Germany
facility: BG-Unfallklinik Ludwigshafen
city: York
country: United Kingdom
facility: York District Hospital
Study officials:
affiliation: BG-Unfallklinik Ludwigshafen
name: Andreas W Wentzensen, Prof. MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Harvard Medical School (HMS and HSDM)
name: Jesse B Jupiter, Prof. MD
role: PRINCIPAL_INVESTIGATOR
affiliation: York District Hospital
name: Peter G De Boer, F.R.C.S.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02214745: Demographic Characteristics of Children Suffering From Mental Retardation or Cerebral Palsy in the Israeli Arab Community
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Mental Retardation
Cerebral Palsy
Keywords: Israeli Arab population
Israeli/ethnology
Lead sponsor: Hillel Yaffe Medical Center
Sponsor class: OTHER_GOV
First posted: 2014-08-12
Enrollment: 400
Sex: ALL
Minimum age (years): 1
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Israeli Arab and Israeli Jewsih children suffering from mental retardation or cerebral palsy who have presented at the Child Development Institute at the Hillel Yaffe Medical Center.

Brief summary: To evaluate the demographic characteristics of patients suffering from mental retardation or cerebral palsy in the Israeli Arab community. Specific questionnaires will be developed and will be distributed amongst this population in order to identify these characteristics.


Eligibility criteria: Inclusion Criteria:

* cerebral palsy
* mental retardation
* Israeli Arab
* Israeli Jewish

Exclusion Criteria:

* all others

Primary outcomes:
measure: Demographic Characteristics
timeFrame: One day
Secondary outcomes:
Other outcomes:
Locations:
city: Hadera
country: Israel
facility: Hillel Yaffe Medical Center
Study officials:
affiliation: Hillel Yaffe Medical Center
name: Muhammad Mahajnah, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00038545: A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma
Official title: A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Patients With Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Non-Hodgkin's Lymphoma
Keywords: LYMPHOMA
NON-HODGKINS
AGGRESSIVE
RELAPSED AND REFRACTORY
Lead sponsor: M.D. Anderson Cancer Center
Sponsor class: OTHER
First posted: 2002-06-03
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: For patients with relapsed and refractory aggressive non-Hodgkin's lymphoma


Eligibility criteria: INCLUSION:

* Bidimensionally measurable current/refractory aggressive NHL (Diffuse lg cell, diffuse mixed cell, follicular lg non-cleaved, immunoblastic, Ki-1+ALCL, peripheral T-cell lymphoma, mantle cell lymphoma \& transformed lymphoma.)
* No more than 3 prior treatment regimens. No anti-lymphoma therapy within the past 3 weeks.
* Not be eligible for treatment of a higher priority.
* Performance status \<2 Zubrod, \> 60 Karnofsky.
* Good marrow reserve: ANC\>1.5 x 10(9)/L, platelets \> 100 x 10(9)/L.
* Bilirubin \<1.5mg/dL, SGOT, SGPT \< 2 x normal values.
* Serum creatinine \< 1.8 mg/dL.
* Age \> 18 yrs.
* Signed informed consent.
* Life expectancy of \> 12 weeks.
* No prior Taxane (paclitaxel or docetaxel), topotecan, or CPT-11.
* No prior stem cell or bone marrow transplantation.
* No prior second malignancies except for basal cell carcinoma of the skin.

EXCLUSION:

* Active or prior history of CNS lymphoma.
* Serious intercurrent medical illnesses requiring hospitalization.
* History of primary/secondary immunodeficiency (other than related to the malignant lymphoma because treatment is dependent on a functional immune system) or patients taking immunosuppressive drugs (systemic corticosteroids).
* Prior exposure to Filgrastim-SD/01.
* Women who are pregnant or lactating.
* Participation in another clinical trial.
* Positive HIV antibody.
* History of prior sensitivity to E. coli derived products (such as filgrastim/neupogen).

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Houston
country: United States
facility: UT MD Anderson Cancer Center
state: Texas
Study officials:
affiliation: UT MD Anderson Cancer Center
name: Anas Younes, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04814745: Intrathecal Morphine for Radical Robot Assisted Prostatectomy (TORNADO)
Official title: Intrathecal Morphine Compared to Intravenous Tramadol and Transversus Abdominal Plane Block for Catheter Related Bladder Discomfort Syndrome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Catheter Related Complication
Lead sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Sponsor class: OTHER
First posted: 2021-03-24
Enrollment: 33
Sex: MALE
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: investigators aim to compare the efficacy of intrathecal morphine, intravenous tramadol and transversus abdominis plane block in the treatment of catheter related bladder discomfort syndrome in patients scheduled for robotic assisted laparoscopic prostatectomy

Detailed description: patients scheduled for robot assisted laparoscopic prostatectomy will be treated depending on the belonging group. In the morphine group patients will receive intrathecal morphine 0,15 mg; in the transversus abdominis plane block patients will receive ropivacaine 80 mg; in the tramadol group patients will receive intravenous continuous infusion of tramadol 400 mg for the first 24 hours postoperatively. All data will be collected in the post anesthesia room and in the ward until the first post operative day.

Eligibility criteria: Inclusion Criteria:

* all patients scheduled for robotic assisted laparoscopic prostatectomy

Exclusion Criteria:

* coagulation disorders and platelet dysfunction for spinal arm
* obesity for transversus abdominis plane block arm
* left ventricular ejection fraction \< 30%, end-stage renal disease and neurological disorders for all groups

Primary outcomes:
measure: catheter related bladder discomfort syndrome
timeFrame: immediately after surgery
Secondary outcomes:
measure: pain relief
timeFrame: immediately after surgery
Other outcomes:
Locations:
city: Roma
country: Italy
facility: Andrea
state: Rome
Study officials:
References:
Clinical trial NCT06203145: A Clinical Study on the Whole-course Management (BCD-KPD-AutoHSCT) Scheme for Patients With RIMM
Official title: A Clinical Study on the Whole-course Management (BCD-KPD-AutoHSCT) Scheme for Patients With Multiple Myeloma and Kidney Injury
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Multiple Myeloma
Renal Injury
Lead sponsor: Peking University First Hospital
Sponsor class: OTHER
First posted: 2024-01-12
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Multiple myeloma (MM) is still an incurable hematological tumor, and renal involvement is the main factor of poor prognosis. The recovery of renal function can partially reverse its poor outcome. Although the 5-year survival rate of MM patients has significantly improved after entering the era of new drugs, patients with severe renal insufficiency still have a high early mortality.The purpose of this study is to investigate whether early intensive chemotherapy can reverse the proportion of renal insufficiency, is to investigate the treatment effect of RIMM patients with different renal pathological types, and is also to investigate whether autoHSCT can further partially save renal function in RIMM patients.

Detailed description: For patients with multiple myeloma with renal impairment, the same disease stage and the same treatment regimen have different therapeutic effects. In the era of new drugs, studies have shown that early reduction of the free light chain in serum is the key to reversing renal function. The International Myeloma Working Group recommends the following drugs for the treatment of RIMM patients: 1. regimens based on proteasome inhibitors; 2. regimens based on immunomodulators. Here, we explore a clinical study on the Whole-course Management (BCD-KPD-AutoHSCT) scheme for patients with RIMM.

Eligibility criteria: Inclusion Criteria:

1. Adults aged 18 years or older
2. Confirmed diagnosis of symptomatic myeloma with renal impairment
3. Confirmed myeloma-associated nephropathy (e.g. light chain cast nephropathy, AL amyloidosis, MIDD etc.) on renal biopsy
4. Willingness and eligibility for autologous hematopoietic stem cell transplantation

Exclusion Criteria:

1. Pre-existing chronic kidney disease unrelated to myeloma, such as diabetic nephropathy or hypertensive nephropathy
2. Plasma cell leukemia or extramedullary plasmacytoma
3. Contraindications or prior severe allergic reactions to study medications
4. Co-existing malignancy
5. Co-existing medical conditions unsuitable for enrollment as determined by researchers, such as recent cardiovascular event, active infection etc.

Primary outcomes:
measure: renal response rates
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking University First Hospital
state: Beijing
Study officials:
References:
Clinical trial NCT01394445: Pilot Study of Physostigmine-Enhanced Opioid Analgesia
Official title: Influence of Physostigmine on Patient-Controlled Analgesia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Postoperative Pain
Lead sponsor: Medical University of Graz
Sponsor class: OTHER
First posted: 2011-07-14
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The investigators hypothesize that the administration of physostigmine in the postoperative period after nephrectomy reduces opioid consumption.


Eligibility criteria: Inclusion Criteria:

* At least 18 years old
* At least 50 kg
* Suitable for PCA
* ASA 1-3

Exclusion Criteria:

* Bronchial asthma/severe or exacerbated COPD
* Iritis
* Stenoses/spasms of intestine, urinary tract, biliary tract
* Closed traumatic brain injury
* Severely reduced left ventricular function (EF\<30%)
* Recent myocardial infarction
* Recent stroke
* Known allergy or hypersensitivity or contraindications against hydromorphone, physostigmine
* History of alcohol or drug abuse
* Patients enrolled in another study
* Women of childbearing age without a negative pregnancy test

Primary outcomes:
measure: opioid consumption
timeFrame: 24 hours
Secondary outcomes:
measure: pain scores
timeFrame: 24 hours
Other outcomes:
Locations:
city: Graz
country: Austria
facility: Hospital of the Medical University of Graz
state: Styria
Study officials:
affiliation: Medical University of Graz
name: Gudrun Rumpold-Seitlinger, MD
role: PRINCIPAL_INVESTIGATOR
References: